Liberty One戰術收益主動型ETF LOTI 深 滬
等待開盤 06-30 09:30:00 美东时间
26.1238
-0.001
0.00%
華盛通- 最 高26.1238
- 今 開26.08
- 成交量 3657股
- 最 低 26.08
- 昨 收 26.1244
- 總市值 4544.97万
- 52周最高 26.5095
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 24.995
- 委 比 0.00%
- 總股本 173.98万
- 歷史最高 26.5095
- 量 比 0.33
- 振 幅 0.17%
- 歷史最低 24.995
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is ADC Therapeutics Stock Falling Thursday?
ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse events despite meeting its primary endpoint.
06-04 20:44
ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA In Combination With Rituximab In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial
06-04 04:13
BRIEF-Tarsus Doses First Participant In Calliope, A Phase 2 Clinical Trial Of Tp-05 (Lotilaner)
BRIEF-Tarsus Doses First Participant In Calliope, A Phase 2 Clinical Trial Of Tp-05 (Lotilaner) March 31 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O : TARSUS DOSES FIRST PARTICIPANT IN CALLIOPE, A PHASE 2 CLINICAL TRIAL OF TP-05 (LOTILANER), A NOVEL INVESTIGATIONAL ORAL TABLET FOR THE POTENTIAL PR
03-31 20:44
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance
Earnings Call Insights: ADC Therapeutics SA (ADCT) Q4 2025 Management View CEO Ameet Mallik highlighted a strategic plan focused on ZYNLONTA with optimized life cycle management, including advancing L...
03-10 22:00
BRIEF-Energy Fuels' US-Produced "Heavy" Rare Earth Oxide Successfully Qualified For Use In Permanent Magnets
Dec 19 (Reuters) - Energy Fuels Inc UUUU.A: ENERGY FUELS' US-PRODUCED "HEAVY" RARE EARTH OXIDE SUCCESSFULLY QUALIFIED FOR USE IN PERMANENT MAGNETS ENERGY FUELS INC: PLANS TO BEGIN PILOTING TERBIUM OXI...
2025-12-19 19:30
BRIEF-Elanco's Credelio Quattro™-Ca1 Receives First FDA Conditional Approval
Dec 18 (Reuters) - Elanco Animal Health Inc ELAN.N: ELANCO'S CREDELIO QUATTRO™-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) RECEIVES FIRST FDA CONDITIONAL APPROVAL FOR TREA...
2025-12-18 22:11
BRIEF-Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta
Dec 3 (Reuters) - ADC Therapeutics SA ADCT.N: ADC THERAPEUTICS ANNOUNCES UPDATED DATA FROM LOTIS-7 PHASE 1B CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH BISPECIFIC ANTIBODY SUPPORTING POTENTIAL BES...
2025-12-03 20:32
BRIEF-Marqeta Announces Appointment Of Mike Milotich As CEO
Sept 8 (Reuters) - Marqeta Inc MQ.O: MARQETA ANNOUNCES APPOINTMENT OF MIKE MILOTICH AS CEO MARQETA INC - MIKE MILOTICH TO CONTINUE AS CFO UNTIL SUCCESSOR FOUND Source text: ID:nBwbZ0LD7a Further compa...
2025-09-08 20:11
BRIEF-Elanco Sells Royalty And Milestone Rights For Lotilaner In Human Health To Blackstone Accelerates Debt Paydown
May 5 (Reuters) - Elanco Animal Health Inc ELAN.N: ELANCO SELLS ROYALTY AND MILESTONE RIGHTS FOR LOTILANER IN HUMAN HEALTH TO BLACKSTONE; ACCELERATES DEBT PAYDOWN ELANCO ANIMAL HEALTH INC - SELLS ROYA...
2025-05-05 18:28
